Open-Label, Non-Randomized, Single Patient Group, Multi-Center Study to Evaluate the Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 30 Oct 2012 Biomarkers information updated
- 21 Dec 2011 New trial record